1263475-93-9

Basic information

• Product Name: 4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl(methyl)amino)pyrimidine-5-carboxylic acid
• Synonyms: 4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl(methyl)amino)pyrimidine-5-carboxylic acid
• CAS NO: 1263475-93-9
• Molecular Weight: 367.401
• Mol File: 1263475-93-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 532.5±60.0 °C(Predicted)
• Density: 1.376±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl(methyl)amino)pyrimidine-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl(methyl)amino)pyrimidine-5-carboxylic acid(1263475-93-9)
• EPA Substance Registry System: 4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl(methyl)amino)pyrimidine-5-carboxylic acid(1263475-93-9)

Safety Data

• Hazardous Substances Data: 1263475-93-9(Hazardous Substances Data)

Usage

General Description

4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl(methyl)amino)pyrimidine-5-carboxylic acid is a complex organic compound with the chemical formula C18H20N4O4S. It is a pyrimidine derivative that contains a fluorophenyl group, an isopropyl group, a methanesulfonyl(methyl)amino group, and a carboxylic acid group. 4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl(methyl)amino)pyrimidine-5-carboxylic acid is often used in pharmaceutical research and development due to its potential therapeutic properties, including its ability to inhibit certain enzymes or receptors in the body. It may also have potential applications in the treatment of certain medical conditions, although further research is needed to fully understand its pharmacological properties and potential uses.

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 1184-85-6 N-methylmethane sulphonamide 
• 488798-38-5 2-chloro-4-(4-fluoro-phenyl)-6-isopropyl-pyrimidine-5-carboxylic acid methyl ester 
• 42558-54-3 Methyl 4-methyl-3-oxopentanoate 
• 1263475-92-8 C₁₉H₂₄FN₃O₄S 
• 147118-30-7 ethyl 2-(N-methyl-N-methanesulfonylamino)-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-5-carboxylic acid 
• 289042-11-1 methyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methanesulphonyl-N-methylamino)pyrimidine-5-carboxylate 

Downstream Products

• 147118-36-3 N-[4-(4-fluorophenyl)-5-(hydroxymethyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 894787-93-0 {(4R,6S)-6-[(E)-2-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid 
• 1378943-63-5 C₂₉H₄₀FN₃O₆S 
• 1333408-83-5 C₂₄H₂₂FN₃O₄S 
• 1333408-82-4 C₂₄H₂₀Cl₂FN₃O₄S 
• 1333408-80-2 C₂₄H₂₁ClFN₃O₄S 
• 1333408-79-9 C₂₄H₂₁BrFN₃O₄S 
• 1333408-78-8 C₂₅H₂₄FN₃O₄S 
• 1333408-77-7 C₂₅H₂₄FN₃O₄S 
• 1333408-68-6 C₂₄H₂₄FN₃O₅S 
• 1333408-65-3 C₂₄H₂₂Cl₂FN₃O₅S 
• 1333408-64-2 C₂₄H₂₃ClFN₃O₅S 
• 1333408-58-4 C₂₅H₂₆FN₃O₅S 

Relevant articles and documents

Stereocontrolled synthesis of rosuvastatin calcium via iodine chloride-induced intramolecular cyclization

A novel, stereoselective approach towards rosuvastatin calcium from the known (S)-homoallylic alcohol has been developed. The synthesis is highlighted by a regio- and stereocontrolled ICl-induced intramolecular cyclization of chiral homoallylic carbonate to deliver the C6-formyl statin side chain with a syn-1,3-diol moiety. An improved synthesis of the rosuvastatin pyrimidine core moiety is also included. Moreover, this methodology is useful in the asymmetric synthesis of structural variants of statins such as pitavastatin calcium and atorvastatin calcium and their related analogs.

Preparation method of rosuvastatin calcium intermediate

The invention provides a preparation method of a rosuvastatin calcium intermediate. The preparation method of the rosuvastatin calcium intermediate, namely, the compound shown as formula I in the description comprises the following steps: (1) a compound 5 shown as formula II in the description is generated from 4-fluorobenzaldehyde, methyl isobutyrylacetate and urea under the action of a catalyst; (2) a compound 6 shown as formula III in the description is generated from the compound 5 under the action of potassium persulfate as an oxidizing agent; (3) a compound 7 shown as formula IV in the description is generated from the compound 6, tosyl chloride and N-methyl methanesulfonamide under the action of a catalyst; (4) the target compound shown as the formula I is generated from the compound 7 under the action of a vitride solution as a reducing agent and crystallized with a crystallization solution, and a purified target compound is obtained. The preparation method of the rosuvastatin calcium intermediate has the advantages of low production cost, mild condition and simple and convenient operation.

METHOD FOR PREPARING ROSUVASTATIN CALCIUM INTERMEDIATE

Disclosed is a method for preparing rosuvastatin calcium intermediate of formula I, which comprises hydrolyzing an ester compound of formula II (R is C1-C5 alkyl) in the presence of a metal compound to obtain a carboxylic acid compound of formula III, and then reducing the carboxylic acid compound under a specific reduction condition to obtain rosuvastatin calcium intermediate of formula I.